Legutko Jacek, Dudek Dariusz, Chyrchel Michał, Rzeszutko Lukasz, Bartuś Stanisław, Heba Grzegorz, Dubiel Jacek S
II Klinika Kardiologii Collegium Medicum, Uniwersytetu Jagiellońskiego w Krakowie.
Przegl Lek. 2005;62(1):1-7.
Borderline coronary lesions are responsible for about 80% of acute coronary syndromes (ACS). Statins have been found to improve long-term prognosis in patients with coronary artery disease due to plaque stabilization. There are no reports on the frequency of new events caused by progression of borderline lesions in patients with (ACS). Percutaneous coronary intervention (PCI) as a method of mechanical stabilization of borderline coronary lesions could be an alternative to pharmacological approach.
To compare the efficacy of pharmacological and mechanical stabilization of borderline plaques (DS = 40-60%) in patients with ACS.
Patients with ACS and angiographically documented borderline lesions, related to the ACS or located in other coronary arteries were enrolled. Patients were randomized to receive pharmacotherapy without intervention or to undergo PCI. The primary end-point was rate of target lesion revascularization with PCI or coronary bypass grafting (CABG) caused by progression of coronary stenosis or in-stent restenosis/thrombosis. The secondary endpoint was incidence of major adverse cardiac events (MACE) at long-term follow-up (death, ST segment elevation acute coronary syndrome--STEACS and non-ST segment elevation acute coronary syndrome-- NSTEACS).
Pharmacological stabilization was used in 50 patients, mean age 56.7 +/- 9.14 years, whereas 44 patients, mean age 57.2 +/- 10.4 years, underwent plaque stabilization with PCI. At follow-up (mean 521 days) target lesion revascularization was performed in 3 patients, previously receiving pharmacotherapy, due to progression of coronary stenosis, and in 3 patients, after prior PCI, due to in-stent restenosis (7% vs. 8%, p = NS). The rate of MACE in both groups was also similar (6% vs. 5%, p = NS).
There were no differences between mechanical and pharmacological stabilization of borderline coronary lesions in patients with acute coronary syndromes.
临界冠状动脉病变约占急性冠状动脉综合征(ACS)的80%。他汀类药物已被发现可通过斑块稳定作用改善冠心病患者的长期预后。目前尚无关于ACS患者临界病变进展导致新事件发生频率的报道。经皮冠状动脉介入治疗(PCI)作为一种机械稳定临界冠状动脉病变的方法,可能是药物治疗方法的替代方案。
比较ACS患者临界斑块(直径狭窄率DS = 40 - 60%)药物稳定和机械稳定的疗效。
纳入有ACS且血管造影记录有与ACS相关或位于其他冠状动脉的临界病变的患者。患者被随机分为接受无干预的药物治疗组或接受PCI组。主要终点是由冠状动脉狭窄进展或支架内再狭窄/血栓形成导致的PCI或冠状动脉旁路移植术(CABG)的靶病变血运重建率。次要终点是长期随访时主要不良心脏事件(MACE)的发生率(死亡、ST段抬高型急性冠状动脉综合征——STEACS和非ST段抬高型急性冠状动脉综合征——NSTEACS)。
50例患者采用药物稳定治疗,平均年龄56.7 +/- 9.14岁,而44例平均年龄57.2 +/- 10.4岁的患者接受了PCI斑块稳定治疗。随访时(平均521天),3例先前接受药物治疗的患者因冠状动脉狭窄进展而进行了靶病变血运重建,3例先前接受PCI治疗的患者因支架内再狭窄进行了靶病变血运重建(7%对8%,p = 无显著性差异)。两组的MACE发生率也相似(6%对5%,p = 无显著性差异)。
急性冠状动脉综合征患者临界冠状动脉病变的机械稳定和药物稳定之间无差异。